NCT07441980

A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients With Relapsed/Refractory Acute Myeloid Leukemia

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Detailed description

This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, efficacy, and cellular pharmacokinetics of CT1390B in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 9\~18 participants in this trial

Conditions

• Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

Type	Name	Description
DRUG	CAR-T cells chimeric antigen receptor T cells	CT1390B cells infusion

Timeline

• Start date: 2026-03-02
• Primary completion: 2026-12-31
• Completion: 2028-06-30
• First posted: 2026-03-02
• Last updated: 2026-03-02

Locations

1 site across 1 country: China